Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | Results from a Phase I study of YTB323, a novel CAR-T therapy in DLBCL

Michael Dickinson • 11 Jun 2022

EHA 2022

Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Tisagenlecleucel YTB323

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the key results of a Phase I study evaluating the use of YTB323, a novel autologous CAR-T therapy, for the treatment of diffuse large B-cell lymphoma (DLBCL). Dr Dickinson first discusses the manufacturing process used in the development of this product, and then highlights the promising results observed in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda

Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma

Michael Dickinson • 16 Jun 2023

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

Michael Dickinson • 16 Jun 2023

Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies

Michael Dickinson et al. • 12 Dec 2022

The challenges in developing bispecific antibodies for non-Hodgkin lymphoma

Michael Dickinson • 30 Sep 2022

Related Videos

Promising novel immunotherapeutic approaches in lymphoma

Gloria Iacoboni • 15 Apr 2024

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024